---
title: "iSERA Lifesciences Ltd (534920) — Share Price, Financials & Analysis"
symbol: "534920"
company: "iSERA Lifesciences Ltd"
canonical: "https://tapetide.com/stocks/534920"
isin: "INE899M01020"
nse_symbol: "COVIDHLTD"
bse_code: "534920"
sector: "Information Technology"
industry: "Computer Software & Consulting"
market_cap_cr: 121
generated_at: "2026-09-13T20:52:43.983Z"
---

# iSERA Lifesciences Ltd (534920)

Canonical page: https://tapetide.com/stocks/534920

## Company

- **NSE Symbol:** COVIDHLTD
- **BSE Code:** 534920
- **ISIN:** INE899M01020
- **Sector:** Information Technology
- **Industry:** Computer Software & Consulting
- **Macro Sector:** Information Technology
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** covidh.co.in

## About

Incorporated in 1993, Covidh Technologies Ltd is engaged in IT/ITES business.[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:33:42.979473Z.

- **Market Cap:** ₹121 Cr
- **Classification:** Microcap
- **P/E (reported):** -2055.7
- **EPS (TTM):** ₹-0.07
- **Book Value:** ₹9.81
- **Price to Book:** 14.67
- **Dividend Yield:** 0%
- **ROE:** -8.82%
- **ROCE:** 4.21%
- **Debt to Equity:** 0.2
- **Revenue (yearly):** ₹25.7 Cr
- **Net Income:** ₹0 Cr
- **EBITDA:** ₹0.5 Cr
- **52-Week High:** ₹143.9
- **52-Week Low:** ₹6.4
- **RSI (14):** 100

## Tapetide Score

- **Score:** 51 / 100
- **Score date:** 2026-08-20
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 53.2 (of 4458 scored stocks)
- **Confidence:** 87%
- **Data coverage:** 74%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 50.9 | 15% |
| growth | 81.14 | 15% |
| momentum | 98.9 | 15% |
| ownership | 50 | 10% |
| quality | 34.95 | 25% |
| valuation | 22.85 | 20% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 14.7 times its book value
- Company has high debtors of 337 days.
- Promoter holding has decreased over last 3 years: -41.4%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 49.23% | -140.74% | -101.86% |
| ebitda margin growth | -100% | 32.62% | 136.71% | — |
| net income growth | -0.1% | -146% | 63% | -32% |
| revenue growth | -69.44% | -23.51% | 0.26% | -9% |
| roce | -100% | 22.74% | -102.04% | — |
| roe | 100% | -721.13% | -810.87% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.19 | 1.16 | 0 |
| Expenses | 0.02 | 0.01 | 0.07 | 0.01 | 0.01 | 0.07 | 0.04 | 0.02 | 0 | 0.47 | 0.59 | 0.34 |
| Operating Profit | -0.02 | -0.01 | -0.07 | -0.01 | -0.01 | -0.07 | -0.04 | -0.02 | 0 | -0.28 | 0.57 | -0.34 |
| OPM % | — | — | — | — | — | — | — | — | — | -147.37 | 49.14 | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0.27 | 0 | 0.01 | 0 | 0.06 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0.02 | -0.01 | -0.07 | -0.01 | -0.01 | -0.07 | 0.23 | -0.02 | 0.01 | -0.28 | 0.63 | -0.34 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.7 | 0 |
| Net Profit | -0.02 | -0.01 | -0.07 | -0.01 | -0.01 | -0.07 | 0.23 | -0.02 | 0.01 | -0.28 | 0.55 | -0.34 |
| EPS in Rs | 0 | 0 | -0.08 | -0.01 | -0.01 | -0.08 | 0.27 | -0.02 | 0.01 | -0.33 | 0.65 | -0.4 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 28.92 | 12.3 | 2.13 | 2.13 | 0 | 0 | 0 | 0.27 | 1.3 | 1.35 |
| Expenses | 28.46 | 11.98 | 2.19 | 0.19 | 0.11 | 0.11 | 0.09 | 0.13 | 1.03 | 1.4 |
| Operating Profit | 0.46 | 0.32 | -0.06 | 1.94 | -0.11 | -0.11 | -0.09 | 0.14 | 0.27 | -0.05 |
| OPM % | 1.59 | 2.6 | -2.82 | 91.08 | — | — | — | 51.85 | 20.77 | -3.7 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.07 | 0.07 |
| Interest | 0.27 | 0.23 | 0.22 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.15 | 0.08 | 0.12 | 0.12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0.04 | 0.01 | -0.4 | 1.8 | -0.11 | -0.11 | -0.09 | 0.14 | 0.34 | 0.02 |
| Tax % | 25 | 200 | 5 | 1.11 | 0 | 0 | 0 | 14.29 | 23.53 | — |
| Net Profit | 0.04 | -0.02 | -0.42 | 1.78 | -0.11 | -0.11 | -0.09 | 0.12 | 0.26 | -0.06 |
| EPS in Rs | 0 | 0 | -0.02 | 0.06 | 0 | 0 | -0.11 | 0.14 | 0.31 | -0.07 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 10.6 | 10.6 | 10.6 | 10.6 | 10.6 | 0.3 | 0.3 | 0.32 | 0.32 | 8.41 |
| Reserves | -10.09 | -10.05 | -10.07 | -10.49 | -10.71 | -0.31 | -0.42 | -0.54 | -0.42 | -0.16 |
| Borrowings | 6.83 | 7.49 | 7.53 | 6.56 | 2.02 | 0 | 0.13 | 0.18 | 1.61 | 1.66 |
| Other Liabilities | 5.57 | 8.19 | 4.12 | 3.81 | 2.59 | 0.02 | 0.04 | 0.1 | 0.05 | 0.65 |
| Total Liabilities | 12.91 | 16.23 | 12.18 | 10.48 | 4.5 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |
| Fixed Assets | 0.44 | 0.45 | 0.75 | 0.62 | 0.43 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 12.47 | 15.78 | 11.43 | 9.86 | 4.07 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |
| Total Assets | 12.91 | 16.23 | 12.18 | 10.48 | 4.5 | 0.01 | 0.05 | 0.06 | 1.56 | 10.56 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -0.63 | -0.51 | 0.34 | 0.97 | 4.45 | -0.3 | -0.12 | -0.06 | -1.4 | -5.35 |
| Cash from Investing Activity | -0.16 | -0.16 | -0.38 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0.06 |
| Cash from Financing Activity | 0.77 | 0.66 | 0.04 | -0.97 | -4.55 | 0.3 | 0.13 | 0.06 | 1.42 | 8.14 |
| Net Cash Flow | -0.02 | -0.01 | 0 | 0 | -0.01 | 0 | 0 | 0 | 0.02 | 2.85 |
| Free Cash Flow | -0.79 | -0.67 | -0.04 | 0.97 | 4.55 | -0.3 | -0.12 | -0.06 | -1.4 | -5.35 |
| CFO/OP | -143 | -109 | 112 | -1650 | 229 | 273 | 109 | 67 | -986 | -1952 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 174.64 | 177.96 | 297.34 | 1470.28 | 498.66 | — | — | — | 419.07 | 336.92 |
| Inventory Days | 0 | 0 | 0 | 0 | — | — | — | — | — | — |
| Cash Conversion Cycle | 174.64 | 177.96 | 297.34 | 1470.28 | 498.66 | — | — | — | 419.07 | 336.92 |
| Working Capital Days | 91.59 | 73.58 | 170.33 | 1041.88 | 260.47 | — | — | — | 351.48 | 224.62 |
| ROCE % | 3.29 | 4.03 | 2.98 | -2.44 | 42.42 | -11.58 | — | — | 19.05 | 5.95 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 100% | 26.35% | 26.35% | 26.35% | 26.35% | 26.35% | 92.76% | 92.76% | 92.76% | 3.57% | 58.63% | 58.63% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 0% | 70.81% | 70.81% | 70.81% | 70.81% | 70.81% | 6.91% | 6.91% | 6.91% | 91.1% | 35.7% | 35.4% |
| Others | 0% | 2.84% | 2.84% | 2.84% | 2.84% | 2.84% | 0.33% | 0.33% | 0.34% | 5.34% | 5.67% | 5.98% |
| No. of Shareholders | 1 | 2530 | 2530 | 2530 | 2530 | 2530 | 932 | 932 | 936 | 1034 | 1029 | 1014 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 9 / 6 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 143.9 | Sell |
| EMA (10) | 143.89 | Buy |
| SMA (20) | 143.9 | Sell |
| EMA (20) | 143.25 | Buy |
| SMA (50) | 138.83 | Buy |
| EMA (50) | 132.88 | Buy |
| SMA (100) | 105.84 | Buy |
| EMA (100) | 110.07 | Buy |
| SMA (200) | 63.04 | Buy |
| EMA (200) | 78.66 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 100 | Sell |
| MACD (12,26,9) | 1.8 | Sell |
| Stochastic (14,3,3) | 50 | Neutral |
| ADX (14) | 100 | Buy |
| Williams %R (14) | -50 | Neutral |
| ATR (14) | 0.16 | Low Volatility |
| ROC (12) | 0 | Neutral |
| Stoch RSI (14) | 50 | Neutral |
| UO (7,14,28) | — | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-07 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=881d167a-ac0a-4065-ab47-887b37caaef2.pdf) |
| 2026-09-05 | [Notice Of 34Th Annual General Meeting Of Isera Lifesciences Limited (Formerly Known As Covidh Technologies Limited) For The Financial Year 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a268b20-ae15-4466-bd2b-aa35e65e22e6.pdf) |
| 2026-09-05 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1dd48b60-a216-4f5b-b3d6-edd19d216679.pdf) |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f637252-b5db-4461-9a46-7d956acb4929.pdf) |
| 2026-09-01 | [Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 01.09.2026 Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=40ff1656-710f-41b0-9b18-e884c38f5f14.pdf) |
| 2026-08-14 | [Submission Of Monitoring Agency Report For Utilization Of Proceeds Of Rights Issue Of Isera Lifesciences Limited (Formerly Known As Covidh Technologies Limited) For The Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=988017fc-4817-451a-bd59-1a1bf7efd50b.pdf) |
| 2026-08-07 | [Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.08.2026 Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55df6deb-cf1d-4d21-bc5e-df6da65328a0.pdf) |
| 2026-08-03 | [Board Meeting Intimation for The Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Friday 7 August 2026 Inter-Alia To Consider Approve And Take On Record The Unaudited Financial Results Of The Company For The Quarter Ended On J](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d8380fd9-2de5-4403-9706-db55f8b7ae6e.pdf) |
| 2026-07-14 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6dbc4d10-2a09-4b7d-a3c7-f09980843551.pdf) |
| 2026-06-29 | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c575a890-c13f-4c97-bb9a-d49de9c78721.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-07 | [Un-Audited Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=36589244-0f08-4e16-b8cf-1ec13d926250.pdf) |
| 2026-05-21 | [We Hereby Submitted The Financial Result For The Financial Year Ended 31 March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2fb5e3b5-b00e-49aa-bd6f-937e28944c2a.pdf) |
| 2026-02-10 | [Results-Financial Results For Quarter Ended 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dab83373-d2ac-4915-b2e1-4eaddd8ef341.pdf) |
| 2025-11-13 | [Un-Audited Financials Results For The Quarter And Half Year Ended 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e22256d5-10dd-4fbf-b10e-f92ed23b5ca8.pdf) |
| 2025-08-01 | [Un-Audited Financial Results Pursuant To Regulation 33 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f7e7f0c-6756-4569-9949-56d045c444eb.pdf) |
| 2025-05-30 | [Audited Financial Results For The Quarter And Year Ended 31.03.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=848b6d67-5ace-4ea5-a5e6-c38d6702f49f.pdf) |
| 2025-02-10 | [Unaudited Financial Results For Quarter Ended 31 December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=661e45e7-65c4-466d-9275-1d5e9d63c002.pdf) |
| 2024-08-12 | [Unaudited Financial Results For Quarter Ended 30 June 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7059cf03-7fd9-42a0-af63-d176fd104225.pdf) |
| 2024-05-29 | [Declaration Of Financial Results For The Quarter And Year Ended 31/03/2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33caa0d8-58ef-47dc-9187-43d978def6a2.pdf) |
| 2024-02-08 | [Results - Unaudited Financial Results For Quarter Ending 31/12/2023.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60093a7b-576f-4c0d-abd1-159272a500db.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 6 Apr - Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, for the quarter and Financial Year ended 31st March 2026 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, for the quarter and Financial Year ended 31st March 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/99a620a0-dc56-4bb8-9dfa-986e67b6f0bf.pdf) |
| 3 Feb - Board meeting on 11 Feb 2026 to consider unaudited Q3/9M FY2026 financial results; trading window closed. | [Board Meeting Intimation for Un-Audited Financial Results (Standalone & Consolidated)For The Quarter And Nine Months Ended 31.12.2025 3 Feb - Board meeting on 11 Feb 2026 to consider unaudited Q3/9M FY2026 financial results; trading window closed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/00194585-a726-485f-8303-478124687dfd.pdf) |
| 3 Apr - EGM on 2 Apr 2026 approved name change to iSERA Lifesciences and four director appointments. | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 3 Apr - EGM on 2 Apr 2026 approved name change to iSERA Lifesciences and four director appointments.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d4d69d9d-53b0-4294-9dad-3b752b196094.pdf) |
| 23 Feb - Non-binding LOI dated Feb 23, 2026 for proposed 100% acquisition of iSERA Biological Limited. | [Announcement under Regulation 30 (LODR)-Acquisition 23 Feb - Non-binding LOI dated Feb 23, 2026 for proposed 100% acquisition of iSERA Biological Limited.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/204d60da-97e1-4290-b4e6-e6e6e2a52cb7.pdf) |
| 23 Feb - LOI dated Feb 23, 2026 for proposed 100% acquisition of iSERA Biological Pvt Ltd, subject to approvals. | [Announcement under Regulation 30 (LODR)-Acquisition 23 Feb - LOI dated Feb 23, 2026 for proposed 100% acquisition of iSERA Biological Pvt Ltd, subject to approvals.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e0f33a30-5d50-4978-9d33-195f3164b427.pdf) |
| 22 Apr - Submission of Newspaper Advertisement of Postal Ballot Notice pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 22 Apr - Submission of Newspaper Advertisement of Postal Ballot Notice pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4deeb040-0e12-46c1-b8ba-d414f7b45227.pdf) |
| 21 Apr - Board approved acquiring iSERA Biological for Rs78.00 crore via 1:1 share swap on 21 April 2026. | [Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association 21 Apr - Board approved acquiring iSERA Biological for Rs78.00 crore via 1:1 share swap on 21 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cefedcd6-fed1-4583-8638-ffcd24ec51f0.pdf) |
| 21 Apr - Board approved 78.00 Cr share-swap acquisition of iSERA Biological, preferential issue of 1.61 crore shares, capital increase. | [Announcement under Regulation 30 (LODR)-Preferential Issue 21 Apr - Board approved 78.00 Cr share-swap acquisition of iSERA Biological, preferential issue of 1.61 crore shares, capital increase.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cdf0e453-fd11-4d77-b641-42402a47b63a.pdf) |
| 21 Apr - Board approved 78.00 Cr share-swap acquisition of iSERA Biological, 1:1 issue of 1.61 crore shares on Apr 21, 2026. | [Revised Outcome Of The Meeting Of The Board Of Isera Lifesciences Limited (Formerly Known As Covidh Technologies Limited) ('The Company') Pursuant To Regulation 29 And 30 Of The SEBI (LODR) Regulations, 2015. 21 Apr - Board approved 78.00 Cr share-swap acquisition of iSERA Biological, 1:1 issue of 1.61 crore shares on Apr 21, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fa598a8c-1b4a-451d-950e-aa154f54f848.pdf) |
| 20 Jan - Special window for re-lodgement of physical share transfers Jul 07, 2025–Jan 06, 2026; no requests. | [SPECIAL WINDOW FOR PHYSICAL SHARES TRANSFER 20 Jan - Special window for re-lodgement of physical share transfers Jul 07, 2025–Jan 06, 2026; no requests.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b932a9e8-c463-4550-bf2b-acb3c976080f.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3c95daf2-ba46-45e4-9496-2ebe9d44479e.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d13f45f0-bee0-4f3a-b970-178ef1ba015f.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1e6ead5b-73c9-4288-8eb8-e81d8a37a5bf.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d4f125f4-2fdf-49f4-8fc5-82e24d53c106.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5eac6ef3-81b0-4379-8c77-306ae6802e38.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7b98dd3f-c7ce-4147-91a9-72d20f1e0e89.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/511768/75872511768.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/534920/76035534920.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/511768/70595511768.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/534920/71739534920.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T20:52:43.983Z.